445 related articles for article (PubMed ID: 23661492)
21. Prevention of glucocorticoid-induced osteoporosis in immunobullous diseases with alendronate: a randomized, double-blind, placebo-controlled study.
Tee SI; Yosipovitch G; Chan YC; Chua SH; Koh ET; Chan YH; Tan SS; Tsou IY; Tan SH
Arch Dermatol; 2012 Mar; 148(3):307-14. PubMed ID: 22105813
[TBL] [Abstract][Full Text] [Related]
22. Four-month metacarpal bone mineral density loss predicts radiological joint damage progression after 1 year in patients with early rheumatoid arthritis: exploratory analyses from the IMPROVED study.
Wevers-de Boer KV; Heimans L; Visser K; Kälvesten J; Goekoop RJ; van Oosterhout M; Harbers JB; Bijkerk C; Steup-Beekman M; de Buck MP; de Sonnaville PB; Huizinga TW; Allaart CF
Ann Rheum Dis; 2015 Feb; 74(2):341-6. PubMed ID: 24285491
[TBL] [Abstract][Full Text] [Related]
23. Baseline glucocorticoid dose and bone mineral density response with teriparatide or alendronate therapy in patients with glucocorticoid-induced osteoporosis.
Devogelaer JP; Adler RA; Recknor C; See K; Warner MR; Wong M; Krohn K
J Rheumatol; 2010 Jan; 37(1):141-8. PubMed ID: 19918047
[TBL] [Abstract][Full Text] [Related]
24. Clinical and radiographic outcome of a treat-to-target strategy using methotrexate and intra-articular glucocorticoids with or without adalimumab induction: a 2-year investigator-initiated, double-blinded, randomised, controlled trial (OPERA).
Hørslev-Petersen K; Hetland ML; Ørnbjerg LM; Junker P; Pødenphant J; Ellingsen T; Ahlquist P; Lindegaard H; Linauskas A; Schlemmer A; Dam MY; Hansen I; Lottenburger T; Ammitzbøll CG; Jørgensen A; Krintel SB; Raun J; Johansen JS; Østergaard M; Stengaard-Pedersen K;
Ann Rheum Dis; 2016 Sep; 75(9):1645-53. PubMed ID: 26489704
[TBL] [Abstract][Full Text] [Related]
25. Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial.
Saag KG; Zanchetta JR; Devogelaer JP; Adler RA; Eastell R; See K; Krege JH; Krohn K; Warner MR
Arthritis Rheum; 2009 Nov; 60(11):3346-55. PubMed ID: 19877063
[TBL] [Abstract][Full Text] [Related]
26. Changes in bone mineral density in patients with recent onset, active rheumatoid arthritis.
Güler-Yüksel M; Bijsterbosch J; Goekoop-Ruiterman YP; de Vries-Bouwstra JK; Hulsmans HM; de Beus WM; Han KH; Breedveld FC; Dijkmans BA; Allaart CF; Lems WF
Ann Rheum Dis; 2008 Jun; 67(6):823-8. PubMed ID: 17644545
[TBL] [Abstract][Full Text] [Related]
27. Changes in bone mineral density following discontinuation or continuation of alendronate therapy in glucocorticoid-treated patients: a retrospective, observational study.
Emkey R; Delmas PD; Goemaere S; Liberman UA; Poubelle PE; Daifotis AG; Verbruggen N; Lombardi A; Czachur M
Arthritis Rheum; 2003 Apr; 48(4):1102-8. PubMed ID: 12687554
[TBL] [Abstract][Full Text] [Related]
28. Modern treatment strategies in rheumatoid arthritis.
Hetland ML
Dan Med Bull; 2011 Nov; 58(11):B4320. PubMed ID: 22047935
[TBL] [Abstract][Full Text] [Related]
29. Effect of intra-articular corticosteroid injections and inflammation on periarticular and generalised bone loss in early rheumatoid arthritis.
Haugeberg G; Morton S; Emery P; Conaghan PG
Ann Rheum Dis; 2011 Jan; 70(1):184-7. PubMed ID: 20805297
[TBL] [Abstract][Full Text] [Related]
30. Effects of alendronate and calcitonin on bone mineral density in postmenopausal osteoporotic women. An observational study.
Hejdova M; Palicka V; Kucera Z; Vlcek J
Pharm World Sci; 2005 Jun; 27(3):149-53. PubMed ID: 16096879
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): additional results from the Monthly Oral Therapy With Ibandronate For Osteoporosis Intervention (MOTION) study.
Emkey R; Delmas PD; Bolognese M; Borges JL; Cosman F; Ragi-Eis S; Recknor C; Zerbini CA; Neate C; Sedarati F; Epstein S
Clin Ther; 2009 Apr; 31(4):751-61. PubMed ID: 19446148
[TBL] [Abstract][Full Text] [Related]
32. Effects of alendronate or alfacalcidol on bone metabolic indices and bone mineral density in patients with ophthalmologic disease treated with glucocorticoid.
Ikeda T; Maruyama K; Kaji H; Akagi M
Mod Rheumatol; 2014 Jul; 24(4):671-6. PubMed ID: 24313921
[TBL] [Abstract][Full Text] [Related]
33. Changes in bone mineral density during long-term treatment with adalimumab in patients with rheumatoid arthritis: a cohort study.
Krieckaert CL; Nurmohamed MT; Wolbink G; Lems WF
Rheumatology (Oxford); 2013 Mar; 52(3):547-53. PubMed ID: 23221326
[TBL] [Abstract][Full Text] [Related]
34. Measurement of hand bone mineral density in early rheumatoid arthritis using dual energy X-ray absorptiometry.
Hill CL; Schultz CG; Wu R; Chatterton BE; Cleland LG
Int J Rheum Dis; 2010 Aug; 13(3):230-4. PubMed ID: 20704619
[TBL] [Abstract][Full Text] [Related]
35. Hand bone loss as an outcome measure in established rheumatoid arthritis: 2-year observational study comparing cortical and total bone loss.
Hoff M; Haugeberg G; Kvien TK
Arthritis Res Ther; 2007; 9(4):R81. PubMed ID: 17705865
[TBL] [Abstract][Full Text] [Related]
36. Tocilizumab potentially prevents bone loss in patients with anticitrullinated protein antibody-positive rheumatoid arthritis.
Chen YM; Chen HH; Huang WN; Liao TL; Chen JP; Chao WC; Lin CT; Hung WT; Hsieh CW; Hsieh TY; Chen YH; Chen DY
PLoS One; 2017; 12(11):e0188454. PubMed ID: 29155868
[TBL] [Abstract][Full Text] [Related]
37. Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis.
Gallagher JC; Rosen CJ; Chen P; Misurski DA; Marcus R
Bone; 2006 Dec; 39(6):1268-75. PubMed ID: 16884968
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of periarticular bone loss is associated with clinical remission and ACR70-Response in rheumatoid arthritis.
Pfeil A; Nussbaum A; Renz DM; Jung C; Oelzner P; Malich A; Wolf G; Böttcher J
Rheumatol Int; 2019 Apr; 39(4):637-645. PubMed ID: 30569216
[TBL] [Abstract][Full Text] [Related]
39. Short- and long-term efficacy of intra-articular injections with betamethasone as part of a treat-to-target strategy in early rheumatoid arthritis: impact of joint area, repeated injections, MRI findings, anti-CCP, IgM-RF and CRP.
Hetland ML; Østergaard M; Ejbjerg B; Jacobsen S; Stengaard-Pedersen K; Junker P; Lottenburger T; Hansen I; Andersen LS; Tarp U; Svendsen A; Pedersen JK; Skjødt H; Ellingsen T; Lindegaard H; Pødenphant J; Hørslev-Petersen K;
Ann Rheum Dis; 2012 Jun; 71(6):851-6. PubMed ID: 22302316
[TBL] [Abstract][Full Text] [Related]
40. Use of bisphosphonate might be important to improve bone mineral density in patients with rheumatoid arthritis even under tight control: the TOMORROW study.
Tada M; Inui K; Sugioka Y; Mamoto K; Okano T; Anno S; Koike T
Rheumatol Int; 2017 Jun; 37(6):999-1005. PubMed ID: 28405825
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
